Leen Vijgen

4.5k total citations
62 papers, 3.1k citations indexed

About

Leen Vijgen is a scholar working on Hepatology, Infectious Diseases and Epidemiology. According to data from OpenAlex, Leen Vijgen has authored 62 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Hepatology, 32 papers in Infectious Diseases and 27 papers in Epidemiology. Recurrent topics in Leen Vijgen's work include Hepatitis C virus research (33 papers), HIV/AIDS drug development and treatment (14 papers) and Viral gastroenteritis research and epidemiology (13 papers). Leen Vijgen is often cited by papers focused on Hepatitis C virus research (33 papers), HIV/AIDS drug development and treatment (14 papers) and Viral gastroenteritis research and epidemiology (13 papers). Leen Vijgen collaborates with scholars based in Belgium, United States and Netherlands. Leen Vijgen's co-authors include Marc Van Ranst, Els Keyaerts, Piet Maes, Johan Neyts, Elien Moës, Philippe Lemey, Sandra Li, Anne–Mieke Vandamme, Inge Thoelen and Elke Wollants and has published in prestigious journals such as Gastroenterology, PLoS ONE and Hepatology.

In The Last Decade

Leen Vijgen

61 papers receiving 3.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Leen Vijgen Belgium 23 2.0k 936 631 573 363 62 3.1k
Jean‐François Rossignol United States 36 1.9k 1.0× 1.3k 1.4× 479 0.8× 242 0.4× 441 1.2× 79 3.8k
Sandrine Belouzard France 31 2.5k 1.3× 1.2k 1.3× 939 1.5× 732 1.3× 1.1k 2.9× 69 5.0k
Fei Yu China 26 1.7k 0.9× 862 0.9× 150 0.2× 264 0.5× 578 1.6× 83 2.8k
Weijin Huang China 30 3.4k 1.7× 737 0.8× 679 1.1× 477 0.8× 1.1k 2.9× 186 4.8k
Sunil K. Lal India 36 2.0k 1.0× 1.0k 1.1× 702 1.1× 442 0.8× 1.6k 4.4× 120 4.7k
Dirk Jochmans Belgium 32 3.1k 1.6× 750 0.8× 185 0.3× 228 0.4× 930 2.6× 94 4.3k
Ming‐Fu Chang Taiwan 38 1.4k 0.7× 1.3k 1.4× 1.2k 1.8× 533 0.9× 1.5k 4.2× 90 4.4k
Seungtaek Kim South Korea 24 957 0.5× 586 0.6× 494 0.8× 80 0.1× 677 1.9× 75 2.4k
Egor P. Tchesnokov Canada 24 2.4k 1.2× 557 0.6× 159 0.3× 122 0.2× 856 2.4× 41 3.4k
Joy Y. Feng United States 30 5.2k 2.6× 822 0.9× 280 0.4× 254 0.4× 1.4k 4.0× 67 6.6k

Countries citing papers authored by Leen Vijgen

Since Specialization
Citations

This map shows the geographic impact of Leen Vijgen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Leen Vijgen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Leen Vijgen more than expected).

Fields of papers citing papers by Leen Vijgen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Leen Vijgen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Leen Vijgen. The network helps show where Leen Vijgen may publish in the future.

Co-authorship network of co-authors of Leen Vijgen

This figure shows the co-authorship network connecting the top 25 collaborators of Leen Vijgen. A scholar is included among the top collaborators of Leen Vijgen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Leen Vijgen. Leen Vijgen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Lawitz, Eric, Fred Poordad, Julio Gutiérrez, et al.. (2020). Simeprevir, daclatasvir, and sofosbuvir for hepatitis C virus‐infected patients: Long‐term follow‐up results from the open‐label, Phase II IMPACT study. Health Science Reports. 3(2). e145–e145. 5 indexed citations
4.
Takehara, Tetsuo, Kazuaki Chayama, Masayuki Kurosaki, et al.. (2020). JNJ-4178 (adafosbuvir, odalasvir, and simeprevir) in Japanese patients with chronic hepatitis C virus genotype 1 or 2 infection with or without compensated cirrhosis: the Phase IIa OMEGA-3 study. Journal of Gastroenterology. 55(6). 640–652. 3 indexed citations
5.
McClure, Matthew W., Elina Berliba, Tengiz Tsertsvadze, et al.. (2018). Safety, tolerability, and pharmacokinetics of AL-335 in healthy volunteers and hepatitis C virus-infected subjects. PLoS ONE. 13(10). e0204974–e0204974. 8 indexed citations
6.
Bourgeois, Stefan, Yves Horsmans, Frederik Nevens, et al.. (2017). Pharmacokinetic Interactions between Simeprevir and Ledipasvir in Treatment-Naive Hepatitis C Virus Genotype 1-Infected Patients without Cirrhosis Treated with a Simeprevir-Sofosbuvir-Ledipasvir Regimen. Antimicrobial Agents and Chemotherapy. 61(12). 6 indexed citations
7.
Vijgen, Leen, Jannick Verbeeck, Jan Martin Berke, et al.. (2013). A Cellular Replicon-Based Phenotyping Assay to Determine Susceptibility of Hepatitis C Virus Clinical Isolates to NS3/4A Protease Inhibitors. Methods in molecular biology. 1030. 105–117. 5 indexed citations
8.
Lenz, Oliver, Leen Vijgen, Jan Martin Berke, et al.. (2012). Virologic response and characterisation of HCV genotype 2–6 in patients receiving TMC435 monotherapy (study TMC435-C202). Journal of Hepatology. 58(3). 445–451. 69 indexed citations
9.
Lenz, Oliver, Bart Fevery, Leen Vijgen, et al.. (2011). TMC435 IN COMBINATION WITH PEGINTERFERON ALPHA-2A/RIBAVIRIN IN TREATMENT-NAiVE PATIENTS INFECTED WITH HCV GENOTYPE 1: VIROLOGY ANALYSIS OF THE PILLAR STUDY. Hepatology. 54. 8 indexed citations
10.
Vijgen, Leen, Elien Moës, Els Keyaerts, Sandra Li, & Marc Van Ranst. (2008). A Pancoronavirus RT-PCR Assay for Detection of All Known Coronaviruses. Methods in molecular biology. 454. 3–12. 65 indexed citations
11.
Keyaerts, Els, Leen Vijgen, Christophe Pannecouque, et al.. (2007). Plant lectins are potent inhibitors of coronaviruses by interfering with two targets in the viral replication cycle. Antiviral Research. 75(3). 179–187. 228 indexed citations
12.
Vijgen, Leen, Els Keyaerts, Philippe Lemey, et al.. (2005). Circulation of genetically distinct contemporary human coronavirus OC43 strains. Virology. 337(1). 85–92. 61 indexed citations
13.
Moës, Elien, Leen Vijgen, Els Keyaerts, et al.. (2005). A novel pancoronavirus RT-PCR assay: frequent detection of human coronavirus NL63 in children hospitalized with respiratory tract infections in Belgium. BMC Infectious Diseases. 5(1). 6–6. 133 indexed citations
14.
Balzarini, Jan, Els Keyaerts, Leen Vijgen, et al.. (2005). Pyridine N-oxide derivatives are inhibitory to the human SARS and feline infectious peritonitis coronavirus in cell culture. Journal of Antimicrobial Chemotherapy. 57(3). 472–481. 67 indexed citations
15.
Keyaerts, Els, et al.. (2005). Viral load quantitation of SARS-coronavirus RNA using a one-step real-time RT-PCR. International Journal of Infectious Diseases. 10(1). 32–37. 18 indexed citations
16.
Balzarini, Jan, Els Keyaerts, Leen Vijgen, et al.. (2004). Inhibitory activity of vancomycin, eremomycin and teicoplanin aglycon derivatives against feline and human coronaviruses (i.e. SARS). Antiviral Research. 62. 4 indexed citations
17.
Balzarini, Jan, Leen Vijgen, Els Keyaerts, et al.. (2004). Mannose-specific plant lectins are potent inhibitors of coronavirus infection including the virus causing SARS. Antiviral Research. 62. 7 indexed citations
18.
Maes, Piet, Barbara Denys, Inge Thoelen, et al.. (2004). Poliovirus sampling by using sodium dodecyl sulfate/EDTA-pretreated chromatography paper strips. Biochemical and Biophysical Research Communications. 325(3). 711–715. 1 indexed citations
19.
Vijgen, Leen, Mark Van Essche, & Marc Van Ranst. (2003). Absence of the Kilifi Mutation in the Rhinovirus-Binding Domain of ICAM-1 in a Caucasian Population. Genetic Testing. 7(2). 159–161. 4 indexed citations
20.
Vijgen, Leen, Annabel Rector, Inge Thoelen, et al.. (2002). Interleukin-1 receptor antagonist VNTR-polymorphism in inflammatory bowel disease. Genes and Immunity. 3(7). 400–406. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jean‐François Rossignol Breakdown of academic impact, for papers by Sandrine Belouzard Breakdown of academic impact, for papers by Fei Yu Breakdown of academic impact, for papers by Weijin Huang Breakdown of academic impact, for papers by Sunil K. Lal Breakdown of academic impact, for papers by Dirk Jochmans Breakdown of academic impact, for papers by Ming‐Fu Chang Breakdown of academic impact, for papers by Seungtaek Kim Breakdown of academic impact, for papers by Egor P. Tchesnokov Breakdown of academic impact, for papers by Joy Y. Feng
Rankless by CCL
2026